Statements (69)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:DNA
|
| gptkbp:anatomy |
lung tissue
|
| gptkbp:associated_with |
gptkb:Oncology
|
| gptkbp:biomarker_role |
predicts response to therapy
|
| gptkbp:breeding_range |
2p21
|
| gptkbp:clinical_trial |
ongoing studies
biomarker for targeted therapy testing new therapies ALK inhibitors |
| gptkbp:code |
EML4 protein
|
| gptkbp:collaborations |
international studies
|
| gptkbp:community |
active interest in gene fusions
|
| gptkbp:discovered_by |
gptkb:2007
|
| gptkbp:disease_mechanism |
involves chromosomal rearrangements
|
| gptkbp:diseases |
gptkb:malignant_pleural_mesothelioma
gptkb:Oncology |
| gptkbp:disruption_effect |
cancer progression
|
| gptkbp:ecological_role |
cellular signaling
|
| gptkbp:expression_level |
varies by cancer type
|
| gptkbp:field_of_study |
molecular biology
|
| gptkbp:function |
microtubule binding
|
| gptkbp:funding |
supported by grants
|
| gptkbp:gene_expression |
regulated by epigenetic factors
|
| gptkbp:gene_expression_profile |
characterized in tumors
|
| gptkbp:genetic_diversity |
single nucleotide polymorphisms
|
| gptkbp:genetic_markers |
used in precision medicine.
|
| gptkbp:genetic_studies |
drug resistance
recommended for families available for patients rearrangement high in lung cancer patients |
| gptkbp:genomic_context |
adjacent to other genes
|
| https://www.w3.org/2000/01/rdf-schema#label |
EML4 gene
|
| gptkbp:impact |
significant in oncology research
|
| gptkbp:involved_in |
anaplastic lymphoma kinase fusion
|
| gptkbp:is_expressed_in |
upregulated in tumors
|
| gptkbp:located_in |
human chromosome 2
|
| gptkbp:mutation_analysis |
important for diagnosis
|
| gptkbp:mutation_detection |
via PCR methods
|
| gptkbp:mutation_impact |
affects treatment response
|
| gptkbp:mutation_screening |
part of routine testing
|
| gptkbp:nutritional_value |
gptkb:ALK_protein
crystal structure available coiled-coil domain microtubule organization nucleus and cytoplasm with various signaling molecules |
| gptkbp:orthologs |
EML4 in other species
|
| gptkbp:pathological_significance |
important in cancer pathology
|
| gptkbp:pathway |
cell cycle regulation
|
| gptkbp:promoter |
gptkb:EML4
gptkb:EML_family cellular component |
| gptkbp:protein_functionality |
critical for cell division
|
| gptkbp:provides_guidance_on |
recommend testing for ALK fusions
|
| gptkbp:publication |
numerous studies
|
| gptkbp:regulatory_compliance |
transcription factors
|
| gptkbp:related_to |
oncogenesis
|
| gptkbp:research |
gene sequencing
|
| gptkbp:research_areas |
targeted therapy
new drugs targeting ALK |
| gptkbp:research_focus |
cancer genetics
|
| gptkbp:seed_dispersal |
protein-coding gene
|
| gptkbp:targets |
ALK fusion protein
|
| gptkbp:therapeutic_strategies |
combination therapies under investigation
|
| gptkbp:transcript_variants |
multiple isoforms
|
| gptkbp:treatment |
prognostic marker
|
| gptkbp:bfsParent |
gptkb:EML4-ALK_fusion_gene
|
| gptkbp:bfsLayer |
8
|